An observational study in Testicular Germ Cell Cancer, Seminoma and Non-Seminoma Testicular Cancer, sponsored by Haukeland University Hospital. Recruiting at 6 sites in 2 countries. Open to male participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-08-08.
Sponsored by Haukeland University Hospital · Observational
The main objective of this study is establish the performance of miR371 in management of testicular cancer
The main objective of the study is to asses the sensitivity and specificity of microRNA-371a-5p (miR371) in detection of viable testicular germ tumour cells. To assess the utility of miR371 at orchiectomy, during treatment and surveillance and in early detection of recurrence.
295 studies on the registry are indexed under Testicular Neoplasms; 51 are open to participants now.
This study's planned enrollment of 350 is above the median of 133 across 73 observational studies indexed under Testicular Neoplasms.
Browse Testicular Neoplasms studies →Haukeland University Hospital is the lead sponsor of 284 studies on the registry; 59 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Men with suspected and confirmed testicular germ cell cancer, aged 18-70 years. Seminomas and non-seminomas, stage I-IV.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood collection. Blood samples will be collected at diagnosis, during surveillance, during treatment and every 3-6 months
miR371 as a biomarker in testicular germ cell cancer at orchiectomy
To estimate the sensitivity and specificity of miR371 in identifying viable tumour cells at diagnosis
Time frame: 5 years
miR371 as a biomarker in testicular germ cell cancer at RPLND
To estimate the sensitivity and specificity of miR371 in identifying viable tumour cells at RPLND
Time frame: 5 years
miR371 as a biomarker in testicular germ cell cancer during chemotherapy treatment
To estimate the performance of miR371 in monitoring of treatment efficiency (chemotherapy)
Time frame: 5 years
miR371 as a biomarker in testicular germ cell cancer and detection of recurrence
To estimate the performance of miR371 in (early) detection of recurrence
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2016 (actual). Primary completion is estimated for Dec 2026, 120 months after the start.
Of 41 observational studies under Testicular Neoplasms, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 191. This study's planned 120 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Haukeland University Hospital →